Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China.

ABSTRACT:

Background

Triple-positive breast cancer (TPBC) is highly invasive and lacks well-established treatment strategies, especially in patients with advanced stage disease. This study aimed to explore the efficacy of everolimus in patients with metastatic TPBC (mTPBC) in a multicenter real-world setting.

Methods

A total of 2518 cancer patients who received everolimus-based therapy were enrolled from three cancer institutes in China from 2014 to 2022. Their clinicopathological characteristics were collected from medical records. The indicators for the efficacy of everolimus were progression-free survival (PFS), objective response rate (ORR) and clinical benefit rate (CBR).

Results

We collected 79 HER2-enriched patients that were treated with everolimus-based therapy, 43 of

SUBMITTER: Tan Y 

PROVIDER: S-EPMC10693944 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature